Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B

Blood Rev. 2022 May:53:100907. doi: 10.1016/j.blre.2021.100907. Epub 2021 Nov 10.

Abstract

There is a dire need to develop an algorithm to improve the recognition of acquired hemophilia A and B (AHA and AHB) in clinical practice. Initial and intensive care unit (ICU) management of the disorder is particular and represents a challenge for the internist/hematologist and the ICU physician. A delay in the proper treatment of bleeding episodes can lead to a life-threatening event. Expert advice should be sought as soon as possible. Succesful resolution involves accurate diagnosis, bleeding control with hemostatic and immunotherapy, and eradication of the autoantibodies to improve overall survival. Current treatment guidelines are based on the literature in the form of cases and observational studies due to a lack of randomized controlled trials. AH can be triggered by many pathologies, presenting as a paraneoplastic syndrome in case of malignancies or as surgical associated acquired hemophilia (SAHA). We have reviewed the literature from 2015 to 2021 regarding the new case reports to further assess if there is an improvement in the clinical approach.

Keywords: Acquired hemophilia; Diagnosis and therapy algoritm; ICU management.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • Hemophilia A* / complications
  • Hemophilia A* / diagnosis
  • Hemophilia A* / therapy
  • Hemorrhage / diagnosis
  • Hemorrhage / etiology
  • Hemorrhage / therapy
  • Hemostatics* / therapeutic use
  • Humans
  • Syndrome

Substances

  • Autoantibodies
  • Hemostatics

Supplementary concepts

  • Factor 8 deficiency, acquired